Rosiglitazone attenuates age‐ and diet‐associated nonalcoholic steatohepatitis in male low‐density lipoprotein receptor knockout mice
Anisha A. Gupte, Joey Z. Liu, Yuelan Ren, Laurie J. Minze, Jessica R. Wiles, Alan R. Collins, Christopher J. Lyon, Domenico Pratico, Milton J. Finegold, Stephen T. Wong, Paul Webb, John D. Baxter, David D. Moore, Willa A. Hsueh – 31 August 2010 – Nonalcoholic fatty liver disease (NAFLD) is a common complication of obesity that can progress to nonalcoholic steatohepatitis (NASH), a serious liver pathology that can advance to cirrhosis. The mechanisms responsible for NAFLD progression to NASH remain unclear.